Healthcare Technologies (MRM) subsidiary gains Japan subsidy program certification

Rhea-AI Filing Summary

Healthcare Technologies Inc. submitted a Form 6-K to inform investors that it issued a press release on a regulatory milestone in Japan. The release explains that a product developed by its subsidiary, MOTHER Labs Inc., has received certification in connection with a governmental subsidy program in Japan. This type of certification can help support adoption of the product by making it eligible for public support, though specific financial terms are not described here. The full details are provided in the attached press release, which is included as Exhibit 99.1.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 08/28/2025 - 04:30 PM Learn about SEC filing dates

FAQ

What did Healthcare Technologies Inc. (MRM) report in this Form 6-K?

The company reported that it issued a press release about certification of a product developed by its subsidiary, MOTHER Labs Inc., for a governmental subsidy program in Japan.

Which subsidiary of Healthcare Technologies Inc. is involved in the certification news?

The subsidiary involved is MOTHER Labs Inc., which developed the product that received certification related to a Japanese governmental subsidy program.

What is the significance of the Japanese governmental subsidy program mentioned for MRM?

The filing notes that a MOTHER Labs product has been certified in connection with a governmental subsidy program in Japan, potentially supporting broader use of the product, though no financial details are provided here.

Where can investors find more details about Healthcare Technologies Inc.'s product certification?

More details are in the press release furnished as Exhibit 99.1 to this Form 6-K.

Is the information in this Healthcare Technologies Inc. Form 6-K considered filed with the SEC?

The company states that the information in this Form 6-K, including Exhibit 99.1, is furnished and not filed for purposes of Section 18 of the Exchange Act, except where specifically incorporated by reference.

Who signed the Form 6-K for Healthcare Technologies Inc. (MRM)?

The Form 6-K was signed on behalf of the company by Fumitoshi Fujiwara, Chief Financial Officer.

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 6-K

​

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

​

For the month of August, 2025

​

Commission File Number 001-39809

​

MEDIROM HEALTHCARE TECHNOLOGIES INC.

(Translation of registrant’s name into English)

​

2-3-1 Daiba, Minato-ku

Tokyo 135-0091, Japan

(Address of principal executive office)

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F

​

​

​

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

Issuance of Press Release

On August 28, 2025, MEDIROM Healthcare Technologies Inc. (the “Company”) is issuing a press release relating to the certification of a product developed by MEDIROM MOTHER Labs Inc., a subsidiary of the Company, in connection with a governmental subsidy program in Japan, as described in more detail in the press release. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information furnished in this report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, as amended, except to the extent specifically provided in such a filing.

​

EXHIBIT INDEX

​

​	​	​
Exhibit No.		Description
99.1	​	Press release of the Company

​

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​	MEDIROM HEALTHCARE TECHNOLOGIES INC.
Date: August 28, 2025	​
​	By:	/s/ Fumitoshi Fujiwara
​	​	Name:	Fumitoshi Fujiwara
​	​	Title:	Chief Financial Officer

​